|
Camille specializes in biotechnology investing at Versant. She joined Versant in early 2000, shortly after its formation. Prior to her experience at Versant, Camille was responsible for business development at Tularik, Inc. (subsequently acquired by Amgen) where she in-licensed two of the company's clinical-stage products and led Tularik's Technology Acquisition Group. Before Tularik, Camille worked in business development/strategic planning at Genzyme and Millennium Predictive Medicine, and as a management consultant to healthcare and biotech companies at LEK Consulting. Camille earned her BS in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow. For more information visit http://www.versantventures.com. | 